Immune-mediated inflammatory diseases (IMIDs) are responsible for substantial global disease burden and associated health-care costs. Traditional models of research and service delivery silo their management within organ-based medical disciplines. Very often patients with disease in one organ have comorbid involvement in another, suggesting shared pathogenic pathways. Moreover, different IMIDs are often treated with the same drugs (including glucocorticoids, immunoregulators and biologics). Unlocking the cellular basis of these diseases remains a major challenge, leading us to ask why, if these diseases have so much in common, they are not investigated in a common manner. A tissue-based, cellular understanding of inflammation might pave the way for cross-disease, cross-discipline basket trials (testing one drug across two or more diseases) to reduce the risk of failure of early-phase drug development in IMIDs. This new approach will enable rapid assessment of the efficacy of new therapeutic agents in cross-disease translational research in humans.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Netea, M. G. et al. A guiding map for inflammation. Nat. Immunol. 18, 826–831 (2017).
El-Gabalawy, H., Guenther, L. C. & Bernstein, C. N. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J. Rheumatol. Suppl. 85, 2–10 (2010).
Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2017).
Conrad, N. et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401, 1878–1890 (2023).
Hemminki, K., Li, X., Sundquist, K. & Sundquist, J. Shared familial aggregation of susceptibility to autoimmune diseases. Arthritis Rheum. 60, 2845–2847 (2009).
Bernstein, C. N., Wajda, A. & Blanchard, J. F. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129, 827–836 (2005).
Thjodleifsson, B., Geirsson, A. J., Björnsson, S. & Bjarnason, I. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum. 56, 2633–2639 (2007).
Kuo, C. F. et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern. Med. 175, 1518–1526 (2015).
Cotsapas, C. et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 7, e1002254 (2011).
Shirai, Y. et al. Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component. Ann. Rheum. Dis. 81, 1301–1312 (2022).
Li, Y. R. et al. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nat. Med. 21, 1018–1027 (2015).
Savic, S., Caseley, E. A. & McDermott, M. F. Moving towards a systems-based classification of innate immune-mediated diseases. Nat. Rev. Rheumatol. 16, 222–237 (2020).
Schett, G., McInnes, I. B. & Neurath, M. F. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N. Engl. J. Med. 385, 628–639 (2021).
McInnes, I. B. & Gravallese, E. M. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat. Rev. Immunol. 21, 680–686 (2021).
Baeten, D. et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann. Rheum. Dis. 77, 1295–1302 (2018).
Deodhar, A. et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 71, 258–270 (2019).
Targan, S. R. et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am. J. Gastroenterol. 111, 1599–1607 (2016).
Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012).
Lee, J. S. et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity 43, 727–738 (2015).
Uzzan, M. et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat. Med. 28, 766–779 (2022).
Parikh, K. et al. Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature 567, 49–55 (2019).
Kinchen, J. et al. Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease. Cell 175, 372–386.e17 (2018).
Huang, B. et al. Mucosal profiling of pediatric-onset colitis and IBD reveals common pathogenics and therapeutic pathways. Cell 179, 1160–1176.e24 (2019).
Corridoni, D. et al. Single-cell atlas of colonic CD8+ T cells in ulcerative colitis. Nat. Med. 26, 1480–1490 (2020).
Smillie, C. S. et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell 178, 714–730.e22 (2019).
Elmentaite, R. et al. Cells of the human intestinal tract mapped across space and time. Nature 597, 250–255 (2021).
Wei, K. et al. Notch signalling drives synovial fibroblast identity and arthritis pathology. Nature 582, 259–264 (2020).
Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20, 928–942 (2019).
Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246–251 (2019).
Alivernini, S. et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat. Med. 26, 1295–1306 (2020).
Martin, J. C. et al. Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy. Cell 178, 1493–1508.e20 (2019).
Friedrich, M. et al. IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nat. Med. 27, 1970–1981 (2021).
Zhang, F. et al. Cellular deconstruction of inflamed synovium defines diverse inflammatory phenotypes in rheumatoid arthritis. bioRxiv Preprint at https://doi.org/10.1101/2022.02.25.481990v1 (2021).
Macnair, W. et al. Single nuclei RNAseq stratifies multiple sclerosis patients into three distinct white matter glia responses. bioRxiv Preprint at https://doi.org/10.1101/2022.04.06.487263v1 (2021).
Korsunsky, I. et al. Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases. Med 3, 481–518.e14 (2022).
Zhang, F. et al. IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation. Genome Med. 13, 64 (2021).
Mulder, K. et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity 54, 1883–1990.e5 (2021).
Rivellese, F. et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat. Med. 28, 1256–1268 (2022).
Humby, F. et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397, 305–317 (2021).
Agrawal, M., Allin, K. H., Petralia, F., Colombel, J. F. & Jess, T. Multiomics to elucidate inflammatory bowel disease risk factors and pathways. Nat. Rev. Gastroenterol. Hepatol. 19, 399–407 (2022).
Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug. Discov. Today 17, 419–424 (2012).
Cook, D. et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat. Rev. Drug. Discov. 13, 419–431 (2014).
Ringel, M., Tollman, P., Hersch, G. & Schulze, U. Does size matter in R&D productivity? If not, what does. Nat. Rev. Drug. Discov. 12, 901–902 (2013).
Woodcock, J. & LaVange, L. M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 377, 62–70 (2017).
Fountzilas, E., Tsimberidou, A. M., Vo, H. H. & Kurzrock, R. Clinical trial design in the era of precision medicine. Genome Med. 14, 101 (2022).
Pitzalis, C., Choy, E. H. S. & Buch, M. H. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nat. Rev. Rheumatol. 16, 590–599 (2020).
Janiaud, P., Serghiou, S. & Ioannidis, J. P. A. New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat. Rev. 73, 20–30 (2019).
Lu, C. C. et al. Practical considerations and recommendations for master protocol framework: basket, umbrella and platform trials. Ther. Innov. Regul. Sci. 55, 1145–1154 (2021).
Collignon, O. et al. Current statistical considerations and regulatory perspectives on the planning of confirmatory basket, umbrella, and platform trials. Clin. Pharmacol. Ther. 107, 1059–1067 (2020).
Park, J. J. H. et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 20, 572 (2019).
Hirakawa, A., Asano, J., Sato, H. & Teramukai, S. Master protocol trials in oncology: review and new trial designs. Contemp. Clin. Trials Commun. 12, 1–8 (2018).
Beckman, R. A., Antonijevic, Z., Kalamegham, R. & Chen, C. Adaptive design for a confirmatory basket trial in multiple tumor types based on a putative predictive biomarker. Clin. Pharmacol. Ther. 100, 617–625 (2016).
Heinrich, M. C. et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin. Cancer Res. 14, 2717–2725 (2008).
Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726–736 (2015).
Thall, P. F. et al. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat. Med. 22, 763–780 (2003).
Chu, Y. & Yuan, Y. A. Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clin. Trials 15, 149–158 (2018).
Zheng, H., Grayling, M. J., Mozgunov, P., Jaki, T. & Wason, J. M. S. Bayesian sample size determination in basket trials borrowing information between subsets. Biostatistics https://doi.org/10.1093/biostatistics/kxac033 (2022).
Ruberg, S. J. et al. Application of Bayesian approaches in drug development: starting a virtuous cycle. Nat. Rev. Drug. Discov. 22, 235–250 (2023).
Meyer, E. L. et al. The evolution of master protocol clinical trial designs: a systematic literature review. Clin. Ther. 42, 1330–1360 (2020).
Park, J. J. H., Hsu, G., Siden, E. G., Thorlund, K. & Mills, E. J. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J. Clin. 70, 125–137 (2020).
FDA Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry. U.S. Food & Drug Administration [online], https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and (2022).
De Benedetti, F. et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N. Engl. J. Med. 378, 1908–1919 (2018).
Tao, J. J., Schram, A. M. & Hyman, D. M. Basket studies: redefining clinical trials in the era of genome-driven oncology. Ann. Rev. Med. 69, 319–331 (2018).
Subbiah, V. et al. Efficacy of vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: an open-label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis. Oncol. 3, 266 (2019). PO.18.00266.
Mazieres, J. et al. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann. Oncol. 31, 289–294 (2020).
Liu, F., Li, N., Li, W. & Chen, C. Impact of clinical center variation on efficiency of exploratory umbrella design. Stat. Biosci. 12, 196–215 (2020).
Diamond, E. L. et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 4, 384–388 (2018).
Trigo, J. et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 21, 645–654 (2020).
Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).
Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209–217 (2019).
He, J. et al. Efficacy and safety of low-dose interleukin 2 for primary Sjögren syndrome: a randomized clinical trial. JAMA Netw. Open. 5, e2241451 (2022).
Wang, J. et al. The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2. Ther. Adv. Chronic Dis. 11, 2040622320916014 (2020).
Miao, M., Li, Y., Huang, B., He, J. & Li, Z. Hypomyopathic dermatomyositis with refractory dermatitis treated by low-dose IL-2. Dermatol. Ther. 10, 1181–1184 (2020).
Zhang, X. et al. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal. Transduct. Target. Ther. 7, 67 (2022).
Humrich, J. Y. et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann. Rheum. Dis. 81, 1685–1694 (2022).
Lähnemann, D. et al. Eleven grand challenges in single-cell data science. Genome Biol. 21, 31 (2020).
Tang, L. Sequencing single cells without killing. Nat. Methods 19, 1166 (2022).
Qiu, P. Embracing the dropouts in single-cell RNA-seq analysis. Nat. Commun. 11, 1169 (2020).
Kharchenko, P. V., Silberstein, L. & Scadden, D. T. Bayesian approach to single-cell differential expression analysis. Nat. Methods 11, 740–742 (2014).
Li, J., Zhang, Y., Yang, C. & Rong, R. Discrepant mRNA and protein expression in immune cells. Curr. Genomics 21, 560–563 (2020).
Trzupek, D. et al. Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. Genome Med. 12, 55 (2020).
Bolton, C. et al. An integrated taxonomy for monogenic inflammatory bowel disease. Gastroenterology 162, 859–876 (2022).
Menis, J., Hasan, B. & Besse, B. New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur. Respir. Rev. 23, 367–378 (2014).
Dooley, A. J., Gupta, A. & Middleton, M. R. Ongoing response in BRAF V600E-mutant melanoma after cessation of intermittent vemurafenib therapy: a case report. Target. Oncol. 11, 557–563 (2016).
Sandri, S. et al. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. Pharmacol. Res. 111, 523–533 (2016).
Sands, B. et al. OP40 PRA023 demonstrated efficacy and favorable safety as induction therapy for moderately to severely active UC: phase 2 ARTEMIS-UC study results. European Crohn’s and Colitis Organisation [online], https://www.ecco-ibd.eu/publications/congress-abstracts/item/op40-pra023-demonstrated-efficacy-and-favorable-safety-as-induction-therapy-for-moderately-to-severely-active-uc-phase-2-artemis-uc-study-results.html (2023).
Alsoud, D., Verstockt, B., Fiocchi, C. & Vermeire, S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol. Hepatol. 6, 589–595 (2021).
Kaizer, A., Zabor, E., Nie, L. & Hobbs, B. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: a comparison of Simon’s two-stage design and Bayesian predictive probability monitoring with information sharing across baskets. PLoS One 17, e0272367 (2022).
S.P.L.T., H.H.U. and C.D.B. are supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), University of Oxford. H.H.U. is supported by The Leona M. and Harry B. Helmsley Charitable Trust.
T.T. has received grants and research support from Celsius Therapeutics, and consulting fees from AbbVie and ZuraBio, and has been an employee of Janssen. H.H.U. has received research support and/or consultancy fees from BMS, Eli Lilly, Janssen, Mestag, OMass and UCB Pharma. S.P.L.T. has received grants and/or research support from AbbVie, Buhlmann, Celgene, Celsius Therapeutics, ECCO, Helmsley Trust, IOIBD, Janssen, Lilly, Pfizer, Takeda, UCB, UKIERI, Vifor and the Norman Collisson Foundation, and consulting fees from Abacus, AbbVie, Actial, ai4gi, Alcimed, Allergan, Amgen, Apexian, Aptel, Arena, Asahi, Aspen, Astellas, Atlantic, AstraZeneca, Bioclinica, Biogen, Boehringer Ingelheim, BMS, Buhlmann, Calcico, Celgene, Cellerix, Cerimon, ChemoCentryx, CisBio, Clario, Coronado, Cosmo, Dynavax, Enterome, EQrX, Equillium, Falk, Ferring, Galapagos, Genentech/Roche, Genzyme, Gilead, GSK, Immunocore, Immunometabolism, Janssen, Lilly, Medarex, Merck, Mestag, Neovacs, Novartis, Novo Nordisk, Otsuka, Pentax, Pfizer, Phesi, Phillips, Protagonist, Proximagen, Resolute, Sandoz, Sanofi, Satisfai, Sorriso, Syndermix, Synthon, Takeda, Theravance, Tigenix, Tillotts, Topivert, TxCell, UCB Pharma, Vertex, VHsquared, Vifor, Warner Chilcott and Zeria, and speaker fees from AbbVie, Amgen, Biogen, BMS, Falk, Ferring, Janssen, Lilly, Pfizer, Shire, Takeda and UCB. No stocks or shares. C.D.B. has received research support and/or consultancy fees from Janssen, GSK, BMS, Celsius, Novartis and Roche, and has stocks or share options for Mestag. T.H. and R.R. declare no competing interests.
Peer review information
Nature Reviews Rheumatology thanks Michelle Rosenzwajg and James Wason for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hosack, T., Thomas, T., Ravindran, R. et al. Inflammation across tissues: can shared cell biology help design smarter trials?. Nat Rev Rheumatol 19, 666–674 (2023). https://doi.org/10.1038/s41584-023-01007-2